What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: DelveInsight | PRODUCT CODE: 1184443

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1184443

Herpes Zoster - Pipeline Insight, 2023

PAGES: 85 Pages
DELIVERY TIME: 1-3 business days
PDF (Single User License)
USD 2000
PDF (Site License)
USD 4000
PDF (Global License)
USD 6000

Add to Cart

DelveInsight's , "Herpes Zoster - Pipeline Insight, 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Herpes Zoster: Understanding

Herpes Zoster: Overview

Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation of varicella-zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection with VZV before in life. VZV is a double-stranded DNA herpes virus with a genome that contains at least 70 gene products that can affect cellular immunity of the body.

VZV is explicitly a human virus that belongs to the α-herpes virus family. It is present worldwide and is highly contagious. More than 90% of adults in the United States acquired the disease in childhood, while the majority of children and young adults have been vaccinated with the live virus vaccine.

Herpes zoster is usually less severe in children than younger adults. It is common in people with diminished cell-mediated immunity which includes older people, patients with lymphoma, those receiving chemotherapy or steroids, and people with HIV. People who earlier had chickenpox are at a higher risk for herpes zoster. VZV-induced neuronal destruction, and inflammation causes pain, interferes with day-to-day activities, and diminish the quality of life.

Commonly, the first symptoms are pain and burning. The pain usually occurs on one side of the body and appears in small patches, followed by red rashes. Polymerase chain reaction (PCR) is the primary method for the diagnosis of herpes zoster as it has very high sensitivity and specificity. Direct fluorescent antibody (DFA) and other antigen-detection methods can be used on biopsy material, and eosinophilic nuclear inclusions and are used as a method for diagnosis. Various treatment methods are in use to treat Acute Herpes zoster, such as corticosteroids, adjuvant agents, analgesics, and others. Pharmacotherapy such as topical lidocaine patch, gabapentin, pregabalin, tricyclic antidepressants, and/or opiates are used to treat Postherpetic Neuralgia (PHN) which is associated with chronic pain. Apart from treatment, various Live Attenuated Zoster Vaccines have been developed, such as Zostavax by Merck, and Subunit Adjuvanted Zoster Vaccine, which has been marketed under the name Shingrix by GlaxoSmithKline.

"Herpes Zoster - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Zoster pipeline landscape is provided which includes the disease overview and Herpes Zoster treatment guidelines. The assessment part of the report embraces, in depth Herpes Zoster commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Zoster collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Zoster R&D. The therapies under development are focused on novel approaches to treat/improve Herpes Zoster.

Herpes Zoster Emerging Drugs Chapters

This segment of the Herpes Zoster report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Herpes Zoster Emerging Drugs

CRV-101: Curevo Inc.

CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. Curevo's CRV-101 is an investigational adjuvanted subunit vaccine for the indication of the prevention of Herpes Zoster in older adults. The adjuvanted subunit vaccine strategy contrasts with traditional approaches using live killed or attenuated viruses. Sub-unit vaccines do not contain virus components and cannot cause infection. The adjuvant component was specifically engineered to produce an optional immune response while using a smaller amount of adjuvant with a targeted structure-function approach. CRV101 is being developed in Phase II stage of development to treat Herpes Zoster.

EG-HZ: EyeGene

A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA05, an adjuvant system which is a non-toxic LOS-derived substance with optimal immunologic activity. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.

ZEP-3: Shulov Institute for Science LTD.

SIS is developing several 'NCE's for anti-inflammatory indications. ZEP-3 possess a unique, combination of pharmacological activities for the treatment of these clinical areas of research. The unique combination of anti-inflammatory and anti-viral activity, in addition to analgesic activity, gives ZEP-3 an advantage over the existing treatments for Herpes Labialis, which are only based on anti-viral activity (Zovirax). Efficacy studies have shown that ZEP-3 is equally effective both on HSV-1 and HSV-2 for acyclovir-resistant viruses. At the same time, a growing population does not respond to the existing therapy because of acyclovir resistance. The Company's ZEP-3 is not based on steroids, thus giving the company a clear and unique advantage. SIS completed a Phase I clinical study on healthy volunteers. This Phase I was suitable for several indications such as: Herpes Labialis, Herpes Zoster, Atopic Dermatitis and Burns.

Further product details are provided in the report……..

Herpes Zoster: Therapeutic Assessment

This segment of the report provides insights about the different Herpes Zoster drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Herpes Zoster

There are approx. 18+ key companies which are developing the therapies for Herpes Zoster. The companies which have their Herpes Zoster drug candidates in the most advanced stage, i.e. Phase II include, Curevo Inc.


DelveInsight's report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes Zoster: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes Zoster therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Zoster drugs.

Herpes Zoster Report Insights

  • Herpes Zoster Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Herpes Zoster Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Herpes Zoster drugs?
  • How many Herpes Zoster drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes Zoster?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Herpes Zoster therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Herpes Zoster and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • EyeGene
  • Shulov Innovative Science
  • Dynavax Technologies
  • Curevo Vaccine
  • Vaccitech
  • NanoViricides
  • Pfizer
  • CPL Biologicals
  • Vapogenix
  • EuBiologics
  • Enzolytics
  • NAL Pharma
  • Gene One Life Science
  • Akshaya Bio
  • Turn therapeutics
  • AIM Vaccine
  • XBiotech
  • HilleVax, Inc.

Key Products

  • EG-HZ
  • ZEP-3
  • CPG 1018 adjuvant
  • CRV101
  • VTP-400
  • NV-HHV-101
  • mRNA based vaccine
  • VZV vaccine
  • Research programme: Inflammatory Pain
  • Herpes Zoster Vaccine
  • Research programme: Monoclonal antibody
  • NAL 3220
  • GLS5100
  • Chimigen ShingVax
  • OV-02
  • Shingles/Herpes Zoster Vaccine
  • Research programme: anti-herpes zoster therapeutic antibodies
Product Code: DIPI0686

Table of Contents


Executive Summary

Herpes Zoster : Overview

  • Introduction
  • Types of RA
  • Pathogenesis
  • Risk factors
  • Diagnosis
  • Signs and Symptoms
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
  • Assessment by Product Type
  • Assessment by Stage and Product Type

Herpes Zoster - DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

CRV1O1: Curevo Vaccine

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

EG-HZ: EyeGene

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical Stage Products

  • Comparative Analysis

mRNA-1468: Moderna

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Herpes Zoster - Collaborations Assessment- Licensing / Partnering / Funding

Herpes Zoster - Unmet Needs

Herpes Zoster - Market Drivers and Barriers


Product Code: DIPI0686

List of Tables

  • Table 1 Total Products for Herpes Zoster
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Herpes Zoster
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!